Keyword: Boehringer Ingelheim
A new study shows SGLT2 diabetes drugs can cut the rate of major cardiovascular events in patients new to treatment.
After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.
New research takes a wide look at the strategy of "evergreening," or adding new patents to extend a drug's exclusivity.
Two new Novo Nordisk ads seem to be typical pharma company spots with middle-aged couples strolling happily along, until they aren't.
Eli Lilly is moving to a new marketing model to manage expenses, but will ad agencies lose work as Lilly looks to bring more services in-house?
Boehringer Ingelheim’s latest campaign for Spiriva Respimat features a "real" bear hugging a sufferer, simulating the crush of asthma symptoms.
AbbVie and Amgen entered a patent settlement that will hold off Amgen's Humira biosimilar in the U.S. until 2023.
Boehringer Ingelheim is developing a model to help predict which patients are best suited for treatment with its SGLT2 medication Jardiance.
AbbVie is thinking about reneging on its 10% price-hike limit announced in January, executives said in a recent meeting with analysts.
Unlike most disease awareness films, Boehringer Ingelheim's latest names a specific treatment, Stiolto Respimat.